Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Azacitidine/Venetoclax

Myelosuppression

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ma J, et al. Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell-Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review. [Review] JCO Precision Oncology 7: e2200693, Sep 2023. Available from: URL: https://dx.doi.org/10.1200/PO.22.00693 Ma J, et al. Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell-Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review. [Review] JCO Precision Oncology 7: e2200693, Sep 2023. Available from: URL: https://​dx.​doi.​org/​10.​1200/​PO.​22.​00693
Metadaten
Titel
Azacitidine/Venetoclax
Myelosuppression
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58007-2

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Etoposide

Case report

Immune-globulin

Case report

Phenylephrine

Case report

Multiple drug